SynthesisMedicine2018
The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.
Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review.Computational and mathematical methods in medicine · 2022Pooled it
- The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.Bioengineered · 2021Pooled it
- Papillary Thyroid Cancer With Cutaneous Metastasis: A Case Report and Literature Review.World journal of otorhinolaryngology - head and neck surgery · 2026Article
- Role ofMolecular and clinical oncology · 2025Review
- The Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals.Biomolecules · 2025Review
- Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.The Journal of clinical endocrinology and metabolism · 2024Article
- The immune cell infiltration-associated molecular subtypes and gene signature predict prognosis for osteosarcoma patients.Scientific reports · 2024Article
- [Possibilities of the personalized approach to solitary thyroid nodules based on molecular profiling].Chirurgie (Heidelberg, Germany) · 2024Review
- Indeterminate Thyroid Nodules: From Cytology to Molecular Testing.Diagnostics (Basel, Switzerland) · 2023Review
- Molecular testing raises thyroid nodule fine needle aspiration diagnostic value.Endocrine connections · 2023Article
- Clinical-Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma.Frontiers in endocrinology · 2022Article
- Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers.Medicina (Kaunas, Lithuania) · 2021Review
- Article
- Leveraging Genetic Reports and Electronic Health Records for the Prediction of Primary Cancers: Algorithm Development and Validation Study.JMIR medical informatics · 2021Article
- Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma.Cancers · 2021Article
- [Diagnostic principles of thyroid tumors in pathology : Relevant changes due to the current WHO classification].Der Pathologe · 2021Article
- Advancements in the treatment of differentiated thyroid cancer.Therapeutic advances in endocrinology and metabolism · 2021Review
- Clinical Utility of BRAF, NRAS, and TERT Promoter Mutation in Preoperative Thyroid Fine-Needle Aspiration Biopsy: A Diagnostic Study From Dharmais Cancer Hospital.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Telomerase reverse transcriptase promoter mutations in thyroid carcinomas: implications in precision oncology-a narrative review.Annals of translational medicine · 2020Review
- Suspicious ultrasound and clinicopathological features of papillary thyroid carcinoma predict the status of TERT promoter.Endocrine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTelomerase reverse transcriptase (TERT) promoter mutations have been described in different pathological types of thyroid cancers (TC). After many types of research focusing on the mutations rate in malignant tumors, the main role of TERT promoter mutations has been changed to the preoperative diagnosis and prognosis of TC, according to their high prevalence in aggressive TC.
methodsWe searched Pubmed, Web of Science, Scopus, and VHL and reviewed the most common 2 mutations C288T and C250T in different types of TC, the association between them and some specific clinicopathological features, and their significance in preoperative diagnosis and prognosis of TC. we chose 38 studies into our qualitative research. We also chose 22 studies to do a meta-analysis on this subject.
resultsThe overall rate of these mutations in different types of TC was 10.0%, with 86.1% C228T mutation, 12% C250T mutation, and 2.1% other type mutations. The rate increases significantly as the TC become more aggressive, and reaches 56.8% in anaplastic thyroid cancer (ATC). Statistically meaningful association is found between TERT promoter mutations and older age, larger tumor size, extrathyroidal extension, lymph node metastasis, distance metastasis, advanced TNM stage, recurrence, and BRAF V600E mutation. Some studies concentrating on DNA sequencing based on fine needle aspiration biopsy (FNAB) also proved their significance in preoperative stage, with 7% to 16.5% sensitivity.
conclusionsTERT promoter mutations were likely to occur in BRAF V600E positive TC. Patients with these 2 combined mutations were more likely to have a poor prognosis and outcome. TERT promoter mutations is an essential part of the ThySeq gene panel. The mechanism of how they influence the appearance and development of TC has not been expounded. The next study direction may be the mechanism exploration and the further study to prove their significance in preoperative diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.